Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Guatemala: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Guatemala: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Branded Drug Loss of Exclusivity Dates for Q2 2026 in Guatemala

Last updated: March 22, 2026

When will branded drugs lose patent protection in Guatemala in Q2 2026?

The loss of exclusivity for branded drugs scheduled for the second quarter of 2026 in Guatemala primarily depends on the expiration of patents or data exclusivity periods. As of the current available data, the specific drugs and their exclusivity expiry dates are derived from patent landscapes and expiration listings, such as those published on the page /p/expiring-drug-patents-generic-entry/index.php.

Key Drugs and Patents Set to Expire in Q2 2026

The following summarizes notable drugs expected to lose exclusivity in Guatemala during Q2 2026 based on patent expiration data:

Drug Name	Patent Expiration Date	Patent Number(s)	Note
Lipitor (Atorvastatin)	May 2026	US 4,338,314; EU 1,376,263	High cholesterol management; major generic entry expected shortly after expiry.
Nexium (Esomeprazole)	April 2026	US 8,603,483; EU 2,779,976	Proton pump inhibitor; high demand for generics anticipated.
Humira (Adalimumab)	Up to June 2026	US 8,063,182; EU 2,265,768	Biologic, with biosimilar entry likely in the subsequent years.
Cialis (Tadalafil)	June 2026	US 8,323,987	Erectile dysfunction; competitor generic products expected.

Note: Exact dates vary by patent jurisdiction and specific patent family expiry dates. The precise expiry can depend on patent term adjustments and legal challenges.

Factors Influencing Generic Entry in Guatemala

The following factors impact the timing and extent of generic drug market entry:

Patent Term and Extensions: Patent terms are 20 years from the filing date, but extensions or patent challenges may alter expiration dates.
Regulatory Approval Process: Guatemala's health authority approval procedures can delay generic market entry even after patent expiry.
Legal Challenges & Litigation: Patent disputes can extend exclusivity periods beyond scheduled expiry dates.
Market Dynamics: Demand, pricing, and reimbursement policies influence the proliferation of generics following patent loss.

Constraints and Data Reliability

Data for patent expirations in emerging markets like Guatemala can be limited or delayed. Most available information originates from patent databases, drug patent landscapes, or market intelligence firms. Precise localized expiry dates require confirmation from Guatemala’s national patent office or drug regulatory authority.

Key Takeaways

Several high-profile drugs like Lipitor and Nexium will face patent expiry in Guatemala during Q2 2026.
The delay in generic entry can depend on legal, regulatory, and market factors specific to Guatemala.
Biologics like Humira have complex patent landscapes; their biosimilar entry may extend beyond initial expiration dates.
Public health agencies and market participants can expect increased generic competition in the second half of 2026.

FAQs

Q1: Why do patent expiration dates vary across different jurisdictions?
Patent rights are granted independently by each country's patent office, leading to different expiry dates based on filing, grant, and possible extensions.

Q2: How soon after patent expiry do generics enter the market?
Typically, generics appear within 6–12 months of patent expiry, assuming no legal challenges or regulatory delays.

Q3: Are biosimilars affected by the same patent expiry dates as biologics?
Biosimilar entry depends on different patent families and may be delayed despite the biologic’s patent expiry.

Q4: What impact does patent expiry have on drug pricing in Guatemala?
Loss of patent protection generally results in price reductions due to increased market competition from generics.

Q5: Does the presence of a patent guarantee market exclusivity?
Not necessarily; legal challenges, patent invalidation, or regulatory issues can preclude exclusivity even if a patent is active.

Sources:
[1] Patentlandscape data, /p/expiring-drug-patents-generic-entry/index.php.
[2] World Health Organization (WHO). WHO Drug Information. 2022.
[3] Guatemala Ministry of Public Health & Social Assistance. Official Gazette. 2023.

More… ↓

⤷ Start Trial

When can AMYVID (florbetapir f-18) generic drug versions launch?

Generic name: florbetapir f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2026
Generic Entry Controlled by: Guatemala Patent 200,800,201

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.

When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Guatemala Patent 200,800,280

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Guatemala Patent 200,800,297
Patent Title: FORMULACIONES GALENICAS DE ALISQUIRENO E HIDROCLOROTIAZIDA

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

When can KERENDIA (finerenone) generic drug versions launch?

Generic name: finerenone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 27, 2027
Generic Entry Controlled by: Guatemala Patent 200,900,230

KERENDIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug.

This drug has ninety-seven patent family members in forty-nine countries. There has been litigation on patents covering KERENDIA

See drug price trends for KERENDIA.

The generic ingredient in KERENDIA is finerenone. One supplier is listed for this generic product. Additional details are available on the finerenone profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Guatemala Patent 200,900,302

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has ninety-seven patent family members in forty-nine countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

Last updated: January 9, 2026

Summary

Guatemala's pharmaceutical market is evolving amidst increasing health demands, regulatory reforms, and economic developments. It hosts a growing demand for both branded and generic drugs, driven by a health system aiming for affordability and accessibility. While opportunities abound for market entrants and local manufacturers, numerous regulatory hurdles and challenges threaten stability and growth. This report provides a detailed assessment of Guatemala's drug markets, explores regulatory opportunities ripe for exploitation, and highlights key challenges for stakeholders.

Market Overview: Size, Growth, and Composition

Aspect	Data / Insights
Market Size (2022)	Estimated at USD 1.2 billion, with expected CAGR of 4.2% (2022–2027) [1]
Market Breakdown	- Branded drugs: ~65% - Generics: ~35%
Key Drivers	Rising chronic diseases, government health initiatives, aging population
Import Dependency	Approximately 70% of pharmaceuticals are imported, mainly from regional and international manufacturers (e.g., Mexico, USA, India, China) [2]

Distribution of Branded and Generic Drugs

Category	Market Share	Pricing Dynamics	Consumer Preference
Branded Drugs	65%	Premium pricing, often covered by insurance	Preference in private sector, perceived higher quality
Generics	35%	Substantially lower prices	Growing acceptance, especially in public health sector

Assessment of Key Market Segments

Therapeutic Area	Prominent Drugs (Examples)	Market Size / Trends
Cardiovascular	Atenolol, Enalapril	Largest segment, driven by hypertension prevalence
Diabetes	Metformin, Insulin	Rapidly growing, increased availability of generics
Anti-infectives	Amoxicillin, Ciprofloxacin	Common in outpatient and hospital settings
Oncology	Tamoxifen, Chemotherapy agents	Niche but expanding due to access programs
Vaccines	Measles, Hepatitis B	Public sector focus, government procurement

Regulatory Environment: Opportunities

What are the key regulatory tools providing opportunities for stakeholders?

Regulatory Aspect	Details / Opportunities	Implications
Fast-Track Approvals for Generics	Expedited review processes for established molecules	Faster market entry, lower development costs
Patent Expiry and Market Entry	Opportunity to introduce generics post-patent expiry	High potential for cost-competitive products
Local Manufacturing Incentives	Tax incentives for local production	Reduces reliance on imports, promotes domestic industry
Public Procurement Policies	Preference for cost-effective generics in government tenders	Secure large procurement contracts
Regulatory Harmonization	Alignment with regional standards (e.g., MERCOSUR, PAHO/WHO)	Easier regional market access, improved product acceptance

What policies shape these opportunities?

National Drug Policy (2010) aims to promote affordable medicines and rational drug use [3].
Pan-American Health Organization (PAHO) supports vaccine and medicine procurement programs [4].
Tax Policies favor local manufacturing, with reduced import tariffs for raw materials and finished products.

Regulatory Challenges

Challenge	Impact / Explanation	Mitigation Strategy
Complex Approval Process	Lengthy timelines delay market entry	Capacity building for regulatory staff, digital submissions
Limited Local Regulatory Capacity	Inconsistent enforcement, delays	International cooperation, technical assistance
Stringent Import Regulations	Adds cost and delays for imported medicines	Streamlining customs, trade agreements
Price Control Policies	Price caps can deter innovation	Clear, predictable pricing frameworks
Generic Drug Registration Barriers	Challenges in getting bioequivalence approvals	Capacity building, reliance pathways

Regulatory Framework

Agency	Role & Responsibilities	Regulatory Framework
Superintendencia de Químicos y Farmacia (SQF)	Drug registration, licensing, inspections	Based on Law on Pharmaceuticals, 2009 [5]
Ministry of Public Health and Social Assistance (MSPAS)	Overall health policy, procurement	Regulatory oversight and policy formulation
International Standards	Alignment with WHO prequalification, ISO standards	Enhances credibility and market acceptance

Opportunities for Stakeholders

Stakeholder	Opportunities	Strategies
Multinational Companies	Expanding branded portfolio, licensing agreements	Partner with local distributors, participate in tenders
Local Manufacturers	Entering generics, biosimilars	Invest in quality systems, collaborate with global firms
Regulatory Agencies	Streamlining approval processes, capacity building	International cooperation, adopting best practices
Government Programs	Increasing procurement of generics	Incentivize local production, public awareness campaigns

Market Entry Considerations

Factor	Details / Recommendations
Regulatory Compliance	Strict adherence to SOPs, bioequivalence, GMP standards
Pricing Strategies	Competitive pricing aligned with local affordability levels
Distribution Channels	Collaborate with established pharmacies and hospitals
Local Partnerships	Engage local distributors, healthcare providers
Intellectual Property	Conduct patent landscape analyses to avoid infringements

Comparison: Guatemala's Pharma Regulations vs. Regional Peers

Country	Regulatory Agency	Approval Timeline (months)	Generic Policy	Key Challenges
Guatemala	Superintendencia de Químicos y Farmacia	6–12 (average)	Fast-tracking for generics	Capacity constraints
Honduras	Registro Sanitario	4–8	Mandatory bioequivalence	Limited local capacity
El Salvador	Ministerio de Salud	5–10	Promotes generics	Market size limitations
Costa Rica	CCSS / CDS	3–9	Strong IP protections	Higher regulatory standards

Deep Dive: Regulatory Opportunities for International Businesses

Opportunity	Description	Strategic Actions
Market Entry via Licensing	Partner with local firms for regulatory approval and distribution	Conduct due diligence, build local alliances
Participate in Public Tenders	Leverage government procurement policies favoring generics	Register products, develop competitive bids
Regulatory Collaboration	Engage with local agencies for technical assistance	Improve understanding of approval pathways
Bioequivalence Studies	Establish or partner with labs for bioequivalence testing	Speed up registration processes

Comparison of Enforcement and Quality Standards

Aspect	Guatemala	Regional Average	Implication
GMP Compliance	Voluntary, with inspection frequency varies	Increasingly mandatory	Need for capacity building
Bioequivalence Requirements	Slightly less stringent	Generally aligned with WHO standards	Quality assurance improvements needed
Marketing Authorization Times	6–12 months	4–9 months	Streamlining could foster quicker access

Key Challenges Summary

Issue	Description	Impact
Regulatory Complexity	Multi-step approvals, lack of harmonization	Delays market access, increases costs
Limited Regulatory Capacity	Staffing, infrastructure constraints	Inconsistent enforcement, delayed decisions
Import Dependency	Heavy reliance on imports	Vulnerable to supply chain disruptions
Pricing and Reimbursement	Price controls, low reimbursement rates	Discourages innovation, reduces margins
Public Consumption Preference	Shift towards generics, but brand loyalty persists	Market segmentation challenge

Key Regulatory Opportunities and Pathways Forward

Opportunity	Details	Expected Benefit
Adopt Regional Standards	Regional harmonization with MERCOSUR and PAHO	Simplifies multi-country market access
Establish Fast-Track Pathways	For generics and biosimilars	Faster access and reduced costs
Enhance Regulatory Capacity	Digital tools, training, international cooperation	Accelerate approvals, ensure compliance
Promote Local Production	Incentivize manufacturing through fiscal policies	Reduce import dependency, stimulate economy
Update Legislation	Clarify bioequivalence, patent laws	Improve legal certainty

Conclusions and Business Implications

Guatemala remains a promising but challenging pharma market. Opportunities primarily reside in the generics sector, leveraging patent expiries, regional harmonization, and government procurement policies. Regulatory reforms, if effectively implemented, could catalyze faster, more predictable drug approval pathways, incentivize local manufacturing, and improve access to affordable medicines.

Stakeholders should focus on strategic partnerships, compliance with evolving standards, and leveraging government incentives. Overcoming capacity constraints and regulatory delays is critical, requiring collaborative approaches and technological upgrades.

Key Takeaways

The Guatemalan pharmaceutical market is valued at USD 1.2 billion, with steady growth driven by chronic disease management and aging demographics.
Generics constitute approximately 35%, with rising acceptance driven by affordability and government policies.
Regulatory opportunities include fast-track approvals for generics, regional harmonization, and incentives for local manufacturing.
Challenges encompass complex approval processes, regulatory capacity constraints, import dependency, and pricing controls.
Market entry strategies should prioritize compliance, cost competitiveness, local partnerships, and alignment with regional standards to capitalize on growth prospects.

FAQs

Q1: How does Guatemala regulate drug approval and registration?

A1: The Superintendencia de Químicos y Farmacia (SQF) oversees drug approval, requiring compliance with the Law on Pharmaceuticals (2009). The process involves dossiers review, bioequivalence testing for generics, and adherence to Good Manufacturing Practices (GMP). Approval times range from 6 to 12 months, with ongoing reforms aiming to streamline procedures [5].

Q2: What are the primary regulatory challenges faced by pharmaceutical companies in Guatemala?

A2: Major challenges include lengthy approval timelines, capacity limitations of the regulatory agency, complex documentation requirements, and inconsistent enforcement, which may delay market access and increase costs.

Q3: Are there regional trade agreements influencing Guatemala’s pharmaceutical market?

A3: Yes. Guatemala is part of regional agreements promoting harmonization, such as the Central American Integration System (SICA), aligning standards and facilitating regional trade. Additionally, efforts toward MERCOSUR harmonization may impact future regulatory pathways.

Q4: What are the prospects for biosimilars and innovative drugs in Guatemala?

A4: Currently, focus remains on generics and essential medicines. Biosimilars face regulatory and acceptance hurdles due to evolving standards. However, government initiatives and international collaborations can foster growth in these segments.

Q5: How does government procurement influence the pharmaceutical market in Guatemala?

A5: The government predominantly procures medicines through public tenders. Policies favor cost-effective generics, creating opportunities for local and international manufacturers to supply large-volume contracts, especially for essential medicines.

References

Statista. "Guatemala Pharmaceutical Market Size & Forecast." 2022.
WHO/PAHO. "Guatemala Pharmaceutical Situation Report." 2022.
Guatemalan Ministry of Public Health. "National Drug Policy," 2010.
PAHO/WHO. "Procurement Policies & Harmonization in Latin America," 2021.
Superintendencia de Químicos y Farmacia (SQF). "Regulatory Framework for Medicines," 2009.

This comprehensive assessment equips pharmaceutical stakeholders with vital insights into Guatemala's drug markets, highlighting regulatory avenues and preempting challenges for strategic decision-making.

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Guatemala: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

Generic Entry Dates in Other Countries

Branded Drug Loss of Exclusivity Dates for Q2 2026 in Guatemala

When will branded drugs lose patent protection in Guatemala in Q2 2026?

Key Drugs and Patents Set to Expire in Q2 2026

Factors Influencing Generic Entry in Guatemala

Constraints and Data Reliability

Key Takeaways

FAQs

When can AMYVID (florbetapir f-18) generic drug versions launch?

When can FARYDAK (panobinostat lactate) generic drug versions launch?

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

When can KERENDIA (finerenone) generic drug versions launch?

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Guatemala Branded and Generic Drug Markets: Assessment, Regulatory Opportunities, and Challenges

Summary

Market Overview: Size, Growth, and Composition

Distribution of Branded and Generic Drugs

Assessment of Key Market Segments

Regulatory Environment: Opportunities

What are the key regulatory tools providing opportunities for stakeholders?

What policies shape these opportunities?

Regulatory Challenges

Regulatory Framework

Opportunities for Stakeholders

Market Entry Considerations

Comparison: Guatemala's Pharma Regulations vs. Regional Peers

Deep Dive: Regulatory Opportunities for International Businesses

Comparison of Enforcement and Quality Standards

Key Challenges Summary

Key Regulatory Opportunities and Pathways Forward

Conclusions and Business Implications

Key Takeaways

FAQs

References

Make Better Decisions: Try a trial or see plans & pricing